Skip to main content
. 2023 Sep 5;10:1184887. doi: 10.3389/fsurg.2023.1184887

Table 2.

Baseline characteristics after propensity score matching.

Group CLD (n = 42) Group Non-CLD (n = 42) P-value
Age (years)a 60.3 (12.85) 60.5 (12.03) 0.923
Sex (%) 0.657
 Male 26 (61.9) 24 (57.1)
 Female 16 (38.1) 18 (42.9)
BMI (kg/m2)b 23.33 (3.06) 23.49 (2.65) 0.783
COPD (%) 3 (7.1) 3 (7.1) >0.999
Hypertension (%) 7 (16.7) 6 (14.3) 0.763
Diabetes mellitus (%) 6 (14.3) 4 (9.5) 0.500
Heart failure (%) 2 (4.8) 1 (2.4) >0.999
Smoking (%) 12 (28.6) 9 (21.4) 0.450
ASA 0.503
I–II 24 (57.1) 27 (64.3)
III 18 (42.9) 15 (35.7)
T stage (%) 0.356
 1–2 4 (9.5) 1 (2.4)
 3–4 38 (90.5) 41 (97.6)
N stage (%)
 0 15 (35.7) 16 (38.1) 0.769
 1 20 (47.6) 17 (40.5)
 2 7 (16.7) 9 (21.4)
Site of primary colorectal cancer (%) 0.797
 Right colon 12 (28.6) 11 (26.2)
 Left colon 14 (33.3) 12 (28.6)
 Rectum 16 (38.1) 19 (45.2)
Neoadjuvant therapy received (%) 11 (26.2) 12 (28.6) 0.807
Treatment modality (%)
 Laparoscopy 42 (100) 42 (100)
 Conventional open 0 (0) 0 (0)
Number of liver metastasis (%) 0.648
 Solitary metastasis 17 (40.5) 14 (33.3)
 2 metastases 12 (28.6) 11 (26.2)
 ≥3 metastases 13 (31) 17 (40.5)
Maximum size of liver metastasis (cm)a 2.85 (2.00–4.23) 2.95 (1.58–4) 0.737
Distribution of liver metastases (%) 0.826
 Unilobar 24 (57.1) 23 (54.8)
 Bilobar 18 (42.9) 19 (45.2)
Extent of Liver Resection 0.608
 Minor resection (<3 segments of liver) 11 (26.2) 9 (21.4)
 Major resection (≥3 segments of liver) 31 (73.8) 33 (78.6)

Values in parentheses are percentages, unless indicated otherwise.

BMI, body mass index; COPD, chronic obstructive pulmonary disease; CLD, chronic liver disease.

a

Values are median (interquartile range: 25–75th percentile).

b

Values are mean (standard deviation).